[PDF] A novel t(9;22;11) translocation involving 11q24 in a patient with chronic myeloid leukemia: A case report | Semantic Scholar (2024)

This was the 5th case of t(6;9;22), in particular, a new variant Ph translocation, and the first successful case treated with flumatinib in the world.

The present data suggest that BCR-ABL gene amplification may be associated with imatinib resistance, which can be overcome with dasatinib, and suggests an alternative therapy strategy for CML involving isodicentric Ph chromosomes.

This study explored the rare concomitant occurrence of coexistence current chromosomal translocation and t(9;22) in CML or acute myeloid leukemia (AML) and found it to be extremely rare.

The association of the combination of chronic myeloid leukemia and chronic lymphocytic leukemia will be reviewed in this chapter with the aim of increasing the understanding of CML further from laboratory bench to clinical bedside.

A CML case with complex chromosomal aberrations not previously observed was evaluated and a four-chromosome translocation involving chromosomal regions including 11p11.2 and 20q11.21 was characterized in detail using array-proven multicolor banding (aMCB), a technique which has proven to be of significance in characterizing breakpoint regions in detail.

This novel case illustrates the use of FISH in metaphase to confirm a new rearrangement not previously described in variant Ph formation and that the present karyotype could have originated by a 1-step mechanism with 4 simultaneous breakages without deletion of ABL1.

Good response with imatinib therapy suggested that a single-event rearrangement was involved in the chromosomal changes, and a CML case with a novel five-way complex translocation involving five chromosomes was reported.

A case of a 26-year-old lady who was diagnosed with chronic myelogenous leukemia at 15 weeks gestation and who had an atypical chromosome t(9;22;11) (q34;q11.2;q13) translocation is reported; she delivered a normal boy and went into molecular complete remission.

It is suggested that patients with variant translocations do not constitute a "warning" category in the imatinib era, regardless of the involvement of different mechanisms, the number of involved chromosomes, or the presence of deletions.

It is suggested that all these aberrations, occurring in >5% of CML with secondary changes, should be denoted major route abnormalities, except for slightly lower frequencies of the most common changes in the latter group.

...

...